Telegraph Hill Partners said Monday that it has raised $310 million for THP III, a new fund. According to the company, the fund will be used to finance “innovative enterprises on the verge of expansion.” Based in San Francisco, Calif., Telegraph Hill Partners is a venture capital firm that focuses on investing in the life science and healthcare sectors.
SAN FRANCISCO, CA–(Marketwired – Jul 29, 2013) – Telegraph Hill Partners (THP), a leading venture capital and growth equity firm dedicated exclusively to life science and healthcare investing, has had its final closing on a new $310 million fund and plans to use it to help finance innovative enterprises on the verge of expansion. The fund, THP III, is Telegraph Hill Partners’ largest since the firm was formed in 2001.
“Capital commitments exceeded our target and represent a new record for THP,” stated Matt Mackowski, Chairman of THP. “We are delighted by the participation of our existing limited partners and are gratified to have added several new investors to the fund. We also thank the leaders of our portfolio companies because their exceptional performance was a key component in enabling our firm to reach this significant milestone.”
Consistent with its previous funds, THP III will invest in companies with advanced technologies that have already demonstrated organic revenue growth and a superior business model. Areas of focus include life science tools, reagents, specialty chemistries, medical technology, medical devices, healthcare IT, healthcare services, agriculture and animal health.
THP utilizes an extensive range of investment structures to effectively address the capital needs of each company. These structures range from venture capital to growth equity to buyouts and secondary acquisitions. With the new fund, Telegraph Hill Partners expects to invest in 10-12 innovative, high-growth companies across the United States. THP’s previous investments include Althea Technologies (acquired by Ajinomoto Co.), Ambion, (acquired by Applied Biosystems Group), Dharmacon (acquired by ThermoFisher), NEXUS Biosystems (acquired by Brooks Automation), LDR (based in Austin, TX) and Vidacare (based in San Antonio, TX).
Ronald Seubert, President and Chief Executive Officer of RareCyte, worked with Telegraph Hill Partners when he held the same positions at Applied Precision, a THP portfolio company that was acquired by GE Healthcare. “THP was an active partner with us. They provided strategic guidance and practical advice in many areas that helped us grow our business, achieve profitability and establish our company as a leading life sciences instruments business.”
About Telegraph Hill Partners
Telegraph Hill Partners, founded in 2001 and based in San Francisco, CA, invests in commercial stage life science, medical technology and healthcare companies. For more information please see www.telegraphhillpartners.com.